The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit

描述（由申请人提供）：奥斯瓦尔多·克鲁兹基金会（FIOCRUZ）治疗和预防艾滋病毒/艾滋病临床试验单位（FioTrials）是设在巴西里约热内卢的一个多学科综合研究中心，与埃文德罗·查加斯临床研究所（IPEC CRS）合作。FioTrials CTU和IPEC CRS共同为“高危”人群和艾滋病毒感染者提供护理，并满足某些被剥夺权利人群的需求。包括男男性行为者（MSM）、变性女性、少数民族、女性以及贫困和/或未受过教育的人。FioTrials CTU和IPEC CRS具有独特的优势，可以为艾滋病临床试验组（ACTG）、艾滋病毒预防试验网络（HPTN）和杀微生物剂试验网络（MTN）提供服务，包括一批领先的研究人员；与国际公认的致力于公共卫生研究的政府组织FIOCRUZ建立伙伴关系；参与者的数量对每个网络的科学议程都是有益的。我们的研究目标是1)评估和实施综合策略（治疗和行为），以防止男男性接触者、变性妇女和妇女感染艾滋病毒；2)评估直肠杀微生物剂对我国男男性接触者人群的安全性、有效性和实用性；3)评估合并感染艾滋病毒个体结核病的新诊断、技术、预防和治疗干预措施；4)评估丙型肝炎的新治疗策略，特别是对合并HI感染的丙型肝炎患者；5)评估新的治疗方法，改进现有的艾滋病毒治疗策略，预防合并症。这些目标的实现将归功于FioTrials CTU出色的基础设施、CRS和以社区为中心的研究战略。

DESCRIPTION (provided by the applicant): The Oswaldo Cruz Foundation (FIOCRUZ) Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials), is a multidisciplinary, integrated research center based in Rio de Janeiro, Brazil that is partnered with the Institute de Pesquisa Clinica Evandro Chagas Clinical Research Site (IPEC CRS), Together the FioTrials CTU and IPEC CRS provide care for both "at-risk" and HIV infected persons and cater to the needs of certain disenfranchised populations, including men who have sex with men (MSM), transgender women, racial minorities, women, and those who are poverty stricken and/or uneducated. The FioTrials CTU and IPEC CRS have unique strengths to offer the AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and Microbicide Trials Network (MTN), including a cadre of leading researchers; a partnership with FIOCRUZ, an internationally-recognized governmental organization dedicated to public health research; and a participant population that compliments the scientific agendas of each network. The goal of our research is to 1) evaluate and implement integrated strategies (therapeutic and behavioral) to prevent HIV acquisition in MSM, transgender women and women; 2) evaluate the safety, efficacy and utility of rectal microbicides for our MSM population; 3) evaluate novel diagnostics, technologies, prevention and treatment interventions for tuberculosis in HIV co-infected individuals; 4) evaluate novel treatment strategies for hepatitis C, particularly for those with HI co-infection; and 5) assess novel therapeutics and improve existing HIV treatment strategies and prevent co-morbidities. Achievement of these objectives will be attributed to the outstanding infrastructure of the FioTrials CTU, its CRS and its community-focused research strategies.